[144] Adaptimmune Therapeutics plc American SEC Filing

Rhea-AI Filing Summary

Form 144 notice: The filer notified the sale of 3,250,000 American Depositary Receipts (ADRs) through J.P. Morgan Securities LLC with an approximate aggregate market value of $230,750, and an approximate sale date of 08/15/2025 on NASDAQ. The filing reports 1,590,309,546 ADRs outstanding. The securities were originally acquired in private placements from the issuer on 09/05/2018 (2,000,000 ADRs) and 01/22/2020 (1,250,000 ADRs), with payment in cash on the acquisition dates. The filer certifies they have no undisclosed material adverse information. The filing shows no securities sold by the seller in the past three months.

Positive

• Clear compliance disclosure with broker, quantity, market value, sale date, and exchange specified
• Acquisition history provided: private placements on 09/05/2018 and 01/22/2020 with cash payment
• Filer certifies no undisclosed material adverse information, supporting regulatory transparency
• No sales in prior three months reported for the selling person

Negative

• None.

Insights

Securities Analyst

TL;DR: Notice of proposed sale of 3.25M ADRs via J.P. Morgan; acquisitions were private placements paid in cash.

The filing is a routine Rule 144 notice disclosing a proposed sale on NASDAQ. It provides clear broker details, quantity, aggregate market value, acquisition dates, and payment method. For investors, the filing documents an insider or holder liquidating stock acquired in private placements rather than open-market purchases. The absence of securities sold in the prior three months and the signers representation about no undisclosed material adverse information are standard disclosures that facilitate compliance and market transparency.

Corporate Governance Expert

TL;DR: This is a compliance-focused disclosure showing planned sale and customary certifications under Rule 144.

The notice meets Rule 144 requirements by specifying the class, broker, sale date, outstanding shares, and acquisition history. The signature representation about material information and the clear listing of private placement origins and cash payment support regulatory transparency. No indications of unusual conditions, trading plan details, or prior recent sales are provided in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Receipts	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	3250000	230750	1590309546	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Receipts	09/05/2018	Private Placement	Issuer			2000000	09/05/2018	Cash
American Depositary Receipts	01/22/2020	Private Placement	Issuer			1250000	01/22/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the quantity and timing of the securities being notified for sale by ADAP?

The filer proposes to sell 3,250,000 ADRs with an approximate sale date of 08/15/2025 on NASDAQ.

Who is the broker handling the proposed sale of ADAP ADRs?

The broker listed is J.P. Morgan Securities LLC, 390 Madison Avenue, New York, NY.

What is the reported aggregate market value and number of ADAP ADRs outstanding?

The filing lists an aggregate market value of $230,750 and 1,590,309,546 ADRs outstanding.

How and when were the ADRs being sold originally acquired?

The ADRs were acquired in private placements from the issuer on 09/05/2018 (2,000,000 ADRs) and 01/22/2020 (1,250,000 ADRs), with cash payment.

Does the filing indicate any securities were sold by the filer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.